Drug Repositioning Strategies for Refueling the Pipeline : Market Research Report

Drug Repositioning Strategies for Refueling the Pipeline

Published: May. 24, 2007 - 20 Pages

Executive Summary: Strategic Considerations; Stakeholder Implications
Introduction
In Vivo Technologies: Real-Time Imaging in Animal Models; Zebra Fish Disease Models; In Vivo Multiplexing
Ex Vivo Technologies: Kinetic Markers; Metabolomics; Metabolon; Gene Logic
In Vitro Cell-Based Technologies: Bionaut Pharmaceuticals; Combinat; Gene Logic
In Silico Technologies: Arachnova; Inpharmatics; Off-label.com; Sosei; Gene Logic
Repositioning Within a Therapeutic Area: Dynogen; Jenken Biosciences; Vicus Therapeutics; BrainCells
Strategies in Drug Repositioning: Technology Strategies; Intellectual Property Strategies; Business Models
Outlook for Drug Repositioning
Tables: 1. Select Technologies for Drug Repositioning; 2. Select Companies with Drug Repositioning Technologies or Programs; 3. Select Collaborations in Drug Repositioning
Figures: 1. Number of FDA-Approved New Molecular Entities (1997-2006) and Total Global R&D Spending, PhRMA Members (1997-2005); 2. In Vivo and Ex Vivo Technologies for Drug Repositioning; 3. In Vitro, Cell-Based Assays for Drug Repositioning; 4. In Silico Technologies for Drug Repositioning

Abstract

Drug companies have historically found new indications for their existing drugs serendipitously. Now, however, to refuel product pipelines and improve profi t margins, many companies are turning to low-risk strategies such as drug repositioning. Biotech companies such as Dynogen, BrainCells, Gene Logic, and Xenogen are developing technology platforms that aid companies in the development of systematic approaches to this low-risk strategy.

Questions Answered in This Spectrum Report:
Many new in vivo, ex vivo, in vitro, and in silico drug repositioning approaches are just now emerging. Which approach is likely to have the greatest success in fi nding unexpected new indications for drugs?

The pharmaceutical industry is beginning to adopt technologies based on metabolomics-the comprehensive analysis of metabolites. Which companies are pursuing metabolomics as their primary approach to drug repositioning?

Gene Logic's Phase R Program covers the up-front costs of drug discovery for companies with which it partners. Has Gene Logic's risky strategy been successful in attracting partners? What other partnering strategies are repositioning companies actively pursuing?

CombinatoRx has developed a high-throughput screening system to evaluate pairs of known compounds for specifi c diseases. What successes has CombinatoRx had in identifying new combinations of known drugs to be used in specific diseases?

An essential part of the business strategy for repositioning compounds is ensuring a strong patent estate. What repositioned drugs are most likely to achieve the strongest patent protection?

Please note, the PDF e-mail from publisher version of this report is for a global site license.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

2/14/2012 - 32

Drug Repositioning Strategies for Refueling the Pipeline

Table of Contents

Abstract